FDA Delays Expedited Filing for Dravet’s Drug in Stoke Case
“`html
Eli Lilly’s Donanemab Receives Full FDA Approval for Early Alzheimer’s Disease
Table of Contents
The Food and Drug Governance (FDA) granted full traditional approval to Eli Lilly’s Donanemab (Jaypirca) on June 21, 2024, for the treatment of early symptomatic Alzheimer’s disease. This approval marks a notable advancement in the fight against the debilitating neurodegenerative disease, offering a new treatment option for a specific patient population.
What is Donanemab and How Does it Work?
Donanemab is a human monoclonal antibody designed to target and clear amyloid plaques, a hallmark of Alzheimer’s disease, from the brain. It effectively works by selectively binding to a modified form of amyloid beta found in plaques, triggering their removal by the body’s immune system. Clinical trials demonstrated that Donanemab slowed cognitive and functional decline in patients with early symptomatic Alzheimer’s disease and evidence of amyloid and tau pathology.
The efficacy of Donanemab was demonstrated in the TRAILBLAZER-ALZ 2 trial, a Phase 3 study involving 1,736 participants. Results published in The New England Journal of Medicine showed that Donanemab slowed clinical decline by 22.3% compared to placebo after 76 weeks of treatment. https://www.nejm.org/doi/full/10.1056/NEJMoa2311341
Patient Selection and Biomarker Confirmation
donanemab is not for all Alzheimer’s patients. The FDA approval specifies that it is indeed indicated for patients with early symptomatic Alzheimer’s disease and confirmed presence of amyloid beta pathology. Confirmation of amyloid pathology is required through a positron emission tomography (PET) scan or cerebrospinal fluid (CSF) analysis. This targeted approach aims to maximize benefit for those most likely to respond to the treatment.
The FDA’s approval letter emphasizes the importance of confirming amyloid status before initiating treatment. https://www.fda.gov/drugs/approved-drug-products/jaypirca-donanemab-06212024 The agency also requires post-marketing studies to further evaluate the long-term safety and effectiveness of Donanemab.
Safety Concerns and ARIA Monitoring
Donanemab carries risks, most notably amyloid-related imaging abnormalities (ARIA). ARIA can manifest as ARIA-E (edema,or swelling in the brain) or ARIA-H (microhemorrhages and superficial siderosis). These abnormalities are typically asymptomatic but can, in rare cases, lead to serious neurological complications.
The prescribing data for Donanemab mandates regular MRI monitoring to detect ARIA. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/216889s000lbl.pdf Healthcare providers are instructed to discontinue treatment if ARIA-E is detected and to carefully manage patients who develop ARIA-H. The clinical trials reported ARIA-E in approximately 12.5% of patients treated with Donanemab and ARIA-H in approximately 14.7%.
Cost and Access to Donanemab
Eli Lilly has announced a list price of $4,500 per infusion for Donanemab.Given the need for regular infusions and MRI monitoring, the total cost of treatment is substantial. The company plans to implement a novel pricing model that includes a “results-based” agreement with payers, where reimbursement is tied to actual clinical benefit.
Access to Donanemab will likely be initially limited by the need for specialized diagnostic testing and infusion centers. Medicare announced on July 11, 2024, that it will cover Donanemab for eligible patients who participate in a registry to collect real-world evidence on its effectiveness.